SCHEMBL3526341

SCHEMBL3526341

CCOCOC1CC2C(=O)NC(C(=O)OCC)CCC=CCCCCCN(Cc3ccc(OC)cc3)C(=O)[N+]2C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MMP1 P03956 2/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ GAA P10253 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ KCNH2 Q12809 1/20 0.31
▸ MCHR1 Q99705 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ MAPKAPK2 P49137 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ MMP3 P08254 1/20 0.31
▸ MMP9 P14780 1/20 0.31
▸ FKBP1A P62942 1/20 0.30
▸ ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL995145 0.93 MMP1 (0.34) ALDH1A1HRH3L3MBTL1MMP1MMP13
SCHEMBL995887 0.89 ALDH1A1 (0.36) ALDH1A1HRH3L3MBTL1MMP1MMP13
SCHEMBL996970 0.87 MCHR1 (0.33) ALDH1A1HRH3L3MBTL1MMP1MMP13
SCHEMBL994826 0.84 ALDH1A1 (0.35) ALDH1A1MMP1POLBKCNH2KDM4E
SCHEMBL3308918 0.82 MCHR1 (0.35) ALDH1A1HRH3L3MBTL1KCNH2MCHR1
SCHEMBL3314022 0.81 ALDH1A1 (0.32) ALDH1A1HRH3GAAKCNH2MCHR1
SCHEMBL2839916 0.79 ALDH1A1 (0.33) ALDH1A1KCNH2MCHR1KDM4ECYP3A4
SCHEMBL2837719 0.78 KCNH2 (0.31) KCNH2MCHR1
SCHEMBL995673 0.76 CTSS (0.47) —
SCHEMBL3308959 0.74 KCNH2 (0.36) KCNH2MCHR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111396-B1 HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES JANSSEN R & D IRELAND (IE) 2013-08-07 — — EP disclosed
US-8383584-B2 HCV inhibiting macrocyclic phenylcarbamates MEDIVIR AB (SE) 2013-02-26 — — US disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 — — US disclosed
US-20100041728-A1 HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES MEDIVIR AB 2010-02-18 — — US disclosed
EP-2111396-A1 HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES Tibotec Pharmaceuticals Ltd. (IE) 2009-10-28 — — EP disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 — — US disclosed
WO-2008096001-A1 HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041728-A1 HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES COPB1, HAVCR2, NOD1 ALDH1A1 922/4885HRH3 4804/4885L3MBTL1 3419/4885
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 ALDH1A1 2716/4885HRH3 160/4885L3MBTL1 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback